{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-001386","form_type":"8-K","ticker":"MD","cik":"0000893949","company_name":"Pediatrix Medical Group, Inc.","filed_at":"2022-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.207731+00:00","generated_at":"2026-06-27T07:16:08.433537+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Mednax Q4 EPS $0.47 ($0.52 adj); revenue $499M; FY22 EBITDA guidance at least $270M","bullets":["GAAP EPS from continuing ops $0.47 versus $0.05 in Q4 2020; adjusted EPS $0.52 versus $0.25.","Revenue $498.5M (+20% YoY), driven by 17.6% same-unit growth (volume +6.3%, reimbursement +11.3%).","Adjusted EBITDA $81M in Q4 ($58.3M prior year); full-year 2021 $265.5M.","Preliminary 2022 adjusted EBITDA guidance at least $270M, excluding CARES Act funds.","Post-quarter refinancing: issued $400M 5.375% notes due 2030, new $450M revolver, $250M term loan; total debt $750M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-001386","json":"https://secwatch.observer/filing/0000950170-22-001386.json","markdown":"https://secwatch.observer/filing/0000950170-22-001386.md","text":"https://secwatch.observer/filing/0000950170-22-001386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/893949/000095017022001386/0000950170-22-001386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/893949/000095017022001386/md-20220217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:16:08.433537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}